b'A FIRST-LINE OPTION FOR PATIENTS WITH TYPE 2IN SEPARATE HEAD-TO-HEAD STUDIES, RYBELSUS DELIVERED DIABETES OFFERING POWERFUL A1C REDUCTION 1 SUPERIOR A1C REDUCTION VS JANUVIA AND JARDIANCE 1-3WAKE UP TO THEFrom baseline to Week 26, RYBELSUS deliveredPIONEER 3: Compared to JanuviaPOSSIBILITIES Superior A1C reductions 1,2 Superior weight loss 1,2Mean change in A1C Primary endpoint Mean change in body weight Confirmatory secondary endpointRYBELSUSRYBELSUSJANUVIARYBELSUSRYBELSUSJANUVIA 7 mg (n=465) 14 mg (n=465) 100 mg (n=467) 7 mg (n=465) 14 mg (n=465) 100 mg (n=467)-1.0 % -1.3 % % -4.8 lb -6.8 lbp0.001 vs Januviap0.001 vs Januvia-0.8 ETD: -3.5 lb (95% CI: -4.4, -2.4) ETD: -5.5 lb (95% CI: -6.6, -4.4) -1.3 lb(Baseline: 8.4%) (Baseline: 8.3%) (Baseline: 8.3%) vs Januvia (Baseline: 201 lb) vs Januvia (Baseline: 201 lb) (Baseline: 200 lb)RYBELSUS is not indicated for weight loss. See Study Design below.ETD=estimated treatment difference.PIONEER 2: Compared to Jardiance, RYBELSUS deliveredSuperior A1C reductions 1,3 Comparable weight loss 1,3For adults with type 2 diabetes Mean change in A1C Primary endpoint Mean change in body weight Confirmatory secondary endpointELIGIBLE PATIENTS To receive offer, 7 mg or PAY AS LITTLE AS 14 mg dose prescriptionRYBELSUSJARDIANCERYBELSUSJARDIANCE $10 must be for a 1-, 2-, or14 mg (n=411)25 mg (n=410) 14 mg (n=411) 25 mg (n=410)3-month supply. For 3 mg dose, offer is limited to-1.3 % % -8.4 lbFOR A 1- TO 3-MONTH 1-month supply only. p0.001 vs Jardiance -0.9 ETD: -0.2 lb (95% CI: -1.5, 1.1)-8.1 lbTHE FIRST TYPE 2 DIABETES PILLPRESCRIPTIONa GLP-1 RA=glucagon-like (Baseline: 8.1%) (Baseline: 8.1%) See Study Design below.vs Jardiance (Baseline: 202 lb) (Baseline: 201 lb)IN ITS CLASS (GLP-1 RA) 1peptide-1 receptor agonist.Indication and Usage ContraindicationsHypoglycemia: Patients receiving RYBELSUS in combination with an RYBELSUS delays gastric emptying and has the potential to impact RYBELSUS (semaglutide) tablets 7 mg or 14 mg is indicated as an adjunct to RYBELSUS is contraindicated in patients with a personal or family historyinsulin secretagogue (e.g., sulfonylurea) or insulin may have an increasedthe absorption of other oral medications. Closely follow RYBELSUS diet and exercise to improve glycemic control in adults with type 2 diabetes. of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrinerisk of hypoglycemia, including severe hypoglycemia. Inform patients usingadministration instructions when coadministering with other oral Neoplasia syndrome type 2 (MEN 2), and in patients with a prior seriousthese concomitant medications of the risk of hypoglycemia and educatemedications and consider increased monitoring for medications with a Limitations of Use hypersensitivity reaction to semaglutide or to any of the excipients inthem on the signs and symptoms of hypoglycemianarrow therapeutic index, such as levothyroxine RYBELSUS has not been studied in patients with a history of pancreatitis.RYBELSUS. Serious hypersensitivity reactions including anaphylaxis and Acute Kidney Injury: There have been postmarketing reports of acuteStudy DesignsConsider other antidiabetic therapies in patients with a history of pancreatitisangioedema have been reported with RYBELSUSkidney injury and worsening of chronic renal failure, which may sometimesPIONEER 3: Head-to-Head vs Januvia 1,2 RYBELSUS is not indicated for use in patients with type 1 diabetes Warnings and Precautions require hemodialysis, in patients treated with GLP-1 receptor agonists,In a double-blind, double-dummy trial with a primary endpoint of meanRisk of Thyroid C-Cell Tumors: Patients should be further evaluated ifincluding semaglutide. Some of these events have been reported in patientschange in A1C from baseline to 26 weeks, 1864 adult patients with type Important Safety Information serum calcitonin is measured and found to be elevated or thyroid noduleswithout known underlying renal disease. A majority of the reported events2 diabetes on metformin alone or metformin with a sulfonylurea were occurred in patients who had experienced nausea, vomiting, diarrhea, orrandomized to RYBELSUS 3 mg (n=466), RYBELSUS 7 mg (n=465), are noted on physical examination or neck imagingdehydration. Monitor renal function when initiating or escalating doses of WARNING: RISK OF THYROID C-CELL TUMORSPancreatitis: Has been reported in clinical trials. Observe patients carefullyRYBELSUS in patients reporting severe adverse gastrointestinal reactions RYBELSUS14 mg (n=465), or Januvia100 mg (n=467), all once daily.In rodents, semaglutide causes dose-dependent and for signs and symptoms of pancreatitis (including persistent severe Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, Confirmatory secondary endpoint: Mean change in body weight from treatment-duration dependent thyroid C-cell tumors at clinicallyabdominal pain, sometimes radiating to the back and which may or mayangioedema) have been reported in patients treated with RYBELSUS.baseline to 26 weeksrelevant exposures. It is unknown whether RYBELSUS causesnot be accompanied by vomiting). If pancreatitis is suspected, discontinueIf hypersensitivity reactions occur, discontinue use of RYBELSUS, treatPIONEER 2: Head-to-Head vs Jardiance 1,3thyroid C-cell tumors, including medullary thyroid carcinomaRYBELSUS and initiate appropriate management; if confirmed, do notpromptly per standard of care, and monitor until signs and symptomsIn an open-label trial with a primary endpoint of mean change in A1C (MTC), in humans as human relevance of semaglutide-inducedrestart RYBELSUSresolve. Use caution in a patient with a history of angioedema orfrom baseline to 26 weeks, 822 adult patients with type 2 diabetes rodent thyroid C-cell tumors has not been determinedDiabetic Retinopathy Complications: In a pooled analysis of glycemicanaphylaxis with another GLP-1 receptor agonist on metformin were randomized to RYBELSUS 14 mg (n=411) orRYBELSUS is contraindicated in patients with a personal or familycontrol trials with RYBELSUS, patients reported diabetic retinopathy Acute Gallbladder Disease: Acute events of gallbladder disease such asJardiance 25 mg (n=410), both once daily.history of MTC and in patients with Multiple Endocrine Neoplasiarelated adverse reactions during the trial (4.2% with RYBELSUS and 3.8%cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist Confirmatory secondary endpoint: Mean change in body weight from trials and postmarketing. In placebo-controlled trials, cholelithiasis was syndrome type 2 (MEN 2). Counsel patients regarding the potentialwith comparator). In a 2-year trial with semaglutide injection involving baseline to 26 weeks reported in 1% of patients treated with RYBELSUS7 mg. Cholelithiasis risk for MTC with the use of RYBELSUSand inform them of patients with type 2 diabetes and high cardiovascular risk, more eventswas not reported in RYBELSUS 14 mg or placebo-treated patients. If symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia,of diabetic retinopathy complications occurred in patients treated withcholelithiasis is suspected, gallbladder studies and appropriate clinical dyspnea, persistent hoarseness). Routine monitoring of serumsemaglutide injection (3.0%) compared to placebo (1.8%). The absolute riskfollow-up are indicated To learn more, visit RYBELSUSpro.comcalcitonin or using thyroid ultrasound is of uncertain value for earlyincrease for diabetic retinopathy complications was larger among patients detection of MTC in patients treated with RYBELSUSwith a history of diabetic retinopathy at baseline than among patientsAdverse ReactionsMost common adverse reactions (incidence 5%) nausea, abdominal pain,References: 1. RYBELSUS[package insert]. Plainsboro, NJ: Novo Nordisk Inc.; January 2023.without a known history of diabetic retinopathy. diarrhea, decreased appetite, vomiting and constipation 2. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin Rapid improvement in glucose control has been associated with a temporaryon glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with Drug Interactions sulfonylurea: the PIONEER 3 randomized clinical trial.JAMA. 2019;321(15):1466-1480. 3. Rodbard HW, worsening of diabetic retinopathy. Patients with a history of diabetic RYBELSUS stimulates insulin release in the presence of elevated bloodRosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 retinopathy should be monitored for progression of diabetic retinopathy glucose concentrations. When initiating RYBELSUS, consider reducingdiabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272-2281. the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemiaRYBELSUS is a registered trademark of Novo Nordisk A/S. aOffer available only to commercially insured patients with RYBELSUS Novo Nordisk is a registered trademark of Novo Nordisk A/S. coverage. Month is defined as 30 days. Maximum savings of $300 All other trademarks, registered and unregistered, are the property of their respective owners. per 1-month supply, $600 per 2-month supply, or $900 per 3-monthPlease see additional Important Safety Information in the Brief Summary of the 2023 Novo NordiskPrinted in the U.S.A. US23RYB00450 September 2023 supply. Eligibility and other restrictions apply.Prescribing Information, including Boxed Warning, on the following pages.'